Impact of high-throughput screening in biomedical research
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
High-throughput screening (HTS) has been postulated in several quarters to be a contributory factor to the decline in productivity in the pharmaceutical industry. Moreover, it has been blamed for stifling the creativity that drug discovery demands. In this article, we aim to dispel these myths and present the case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cell-based phenotypic screening of chemical libraries represents a powerful tool to identify new potential drugs48.”
From Identification and characterization of Cardiac Glycosides as senolytic compounds (2019) · cites this paper as [48]
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“HTS laboratories have pioneered and implemented rigorous quality assurance methods, such as Z′ trend monitoring”
MethodCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“These efforts typically take 2–3 years in most drug discovery companie”
BackgroundDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · cited 1×
“There have been numerous analyses of pharmaceutical industry productivity, and several of these have blamed high-throughput screening (HTS) as a factor undermining the creativity that has sustained the industry over the past centur”
BackgroundDiscovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
Hit and lead generation: beyond high-throughput screening
Bleicher, K. H., Böhm, H.-J., Müller, K., & Alanine, A. I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1086 · Cited by 1,056
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939 · cited 1×
“This approach was used to discover compounds that inhibited hepatitis C virus replication and, after consequent optimization, the approach yielded efficacious clinical candidates with a broad genotype coverag”
MethodA Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806
Research works printed but not linked: 5
- Landers, P. Human Element: drug industry's big push into technology falls short — testing machines were built to streamline research — but may be stifling it — officials see payoff after 2010. The Wall Street Journal 1 (24 Feb 2004).
- Mullin, R. As high-throughput screening draws fire, researchers leverage science to put automation into perspective. Chem. Eng. News 82, 23–32 (2004).
- HTStec Limited. Cellular Assay Reagents Trends 2009 Report (Cambridge, UK, 2009).
- LaMattina, J. L. (ed.) in Drug Truths: Dispelling the Myths About Pharma R&D 65–66 (John Wiley and Sons, Inc., Hoboken, New Jersey, 2009).
- Inglese, J. in Ask the Expert Forum, ACS Chemical Biology. ACS Publications [online] http://community.acs.org/ChemBiol/AsktheExpert/AsktheExpertArchive/tabid/67/Default.aspx (2008).
Cited by
Items 801–900 of 1,000
Lopez, M., Leroy, M., Etiévant, C., Ausseil, F., Gagnon, A., & Arimondo, P. B. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802208-5.00003-5 · Cited by 8
Emery, A. C. (2013) · Advances in pharmacology · doi:10.1016/b978-0-12-411512-5.00016-6 · Cited by 8
“2009, and the CCR5 receptor antagonist maraviroc (marketed as Selzentry by Pfizer) was identified by screening in 1997 and was approved for clinical use in 2007 (Macarron et al., 2011).”
BackgroundMethodInfluentialscTREAT: Latent Diffusion for Single-Cell Drug-Response PredictionPreprint
Liang, Z., Zhuang, S., Jiao, X., Mao, W., Chen, H., & Shen, C. (2025) · arXiv (Cornell University) · doi:10.48550/arxiv.2510.11726 · Cited by 8
“While enabling parallel observation of drug effects at some scale, traditional high-throughput screening (HTS) workflows (Mayr & Bojanic, 2009; Macarron et al., 2011; Iversen et al., 2012) are extremely costly in terms of reagents, personnel time, and turnaround.”
Ning, K., Roy, A., Cheng, F., Xu, P., Kleiboeker, S. B., Escalante, C. R., Wang, J., & Qiu, J. (2022) · PubMed · doi:10.1128/jvi.01326-21 · Cited by 7
“HTS has become a mainstay for antiviral discoveries (54), and numerous well-character-”
BackgroundNazeri, M., Watchorn, J., Mei, S., Zhang, A., Allen, C. J., & Gu, F. (2025) · HardwareX · doi:10.1016/j.ohx.2025.e00653 · Cited by 7
“The ability to simultaneously prepare and analyze formulations from multiple combinations of experimental parameters allows exploring vast formulation spaces efficiently, particularly in the development of complex systems like polymers, biomaterials, and drug delivery vehicles [32,33].”
Zimmermann, S., Gretzinger, S., Scheeder, C., Schwab, M., Oelmeier, S. A., Osberghaus, A., Gottwald, E., & Hubbuch, J. J. (2016) · Biotechnology Journal · doi:10.1002/biot.201500577 · Cited by 7
Emerging Technologies for Fragment Screening
Ohlson, S., & Duong‐Thi, M. (2016) · Methods and principles in medicinal chemistry · doi:10.1002/9783527683604.ch08 · Cited by 8
de Magalhães, J. P., & Tăcutu, R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-411596-5.00009-5 · Cited by 7
He, S., & Lim, G. E. (2022) · Advanced Biology · doi:10.1002/adbi.202200151 · Cited by 8
Pesqueira, A. M. (2022) · EAI/Springer Innovations in Communication and Computing · doi:10.1007/978-3-031-17960-0_2 · Cited by 7
Improving Compound–Protein Interaction Prediction by Self-Training with Augmenting Negative Samples
Koyama, T., Matsumoto, S., Iwata, H., Kojima, R., & Okuno, Y. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00269 · Cited by 7
A Systematic Review of AI-Driven Innovations in Drug Development, Precision Medicine, and Healthcare
Uriti, S. V. (2025) · Journal of Pharma Insights and Research. · doi:10.69613/nvj8x122 · Cited by 8
Advancing Organic Chemistry Using High‐Throughput Experimentation
Nsouli, R., Galiyan, G., & Ackerman, L. K. G. (2025) · Angewandte Chemie · doi:10.1002/ange.202506588 · Cited by 7
The Role of Chemogenomics in the Pharmaceutical Industry
Bieler, M., & Koeppen, H. (2012) · Drug Development Research · doi:10.1002/ddr.21026 · Cited by 7
“During the last years, HTS has become an indispensable part of the research strategy of most pharmaceutical companies and contributed to many success stories [Macarron et al., 2011].”
BackgroundStructure-Based Discovery of GPCR Ligands from Crystal Structures and Homology Models
Ranganathan, A., Rodriguez, D. J., & Carlsson, J. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_25 · Cited by 8
Biomolecular Talks—Part 2: Applications and Challenges of Molecular Docking Approaches
Ramaswamy, A., Balasubramanian, S., & Rajagopalan, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822312-3.00024-2 · Cited by 10
Investigating Mammalian Formins with SMIFH2 Fifteen Years in: Novel Targets and Unexpected Biology
Innocenti, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109058 · Cited by 8
“Since the late 1990s, HTS has been a mainstay of hit identification, the process whereby chemical hits for the development of drug candidates for a certain target are discovered [40].”
BackgroundDas, A., Nandi, A., Kumari, V., & Alvala, M. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815179934123010008 · Cited by 13
Design and Synthesis of Cyclic Dinucleotide Analogues Containing Triazolyl C-Nucleosides
Ma, J., Xu, H., Hou, K., Cao, Y., Xie, D., Yan, J., Dong, W., Jiang, T., & Chen, C.-P. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c01055 · Cited by 7
Development of a Novel Screening Strategy Designed to Discover a New Class of HIV Drugs
Cheng, N., Lee, S.-K., Donover, P. S., Reichman, M., Schiffer, C. A., Hull-Ryde, E. A., Swanstrom, R. I., & Janzen, W. P. (2013) · SLAS TECHNOLOGY · doi:10.1177/2211068213513453 · Cited by 7
Self-citationMinas, G., Rigat, F., Nichols, T. E., Aston, J. A. D., & Stallard, N. (2011) · Statistics in Medicine · doi:10.1002/sim.4395 · Cited by 6
“The development of high-throughput biological assays lies at the heart of the emerging concept of personalised medicine [1, 2].”
CHALLENGES IN SECONDARY ANALYSIS OF HIGH THROUGHPUT SCREENING DATA
Blucher, A., & McWeeney, S. K. (2013) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789814583220_0012 · Cited by 7
“8 These problems are can be resolved through pre-processing, standardization and normalization methods, which include the z-score, percent inhibition, and median-based methods among others.”
MethodArid awakening: new opportunities for Australian plant natural product research
Simpson, B. S., Bulone, V., Semple, S. J., Booker, G. W., McKinnon, R. A., & Weinstein, P. (2016) · The Rangeland Journal · doi:10.1071/rj16004 · Cited by 7
Alt, A. J. (2016) · Current Protocols in Pharmacology · doi:10.1002/cpph.12 · Cited by 8
A chemoselective and continuous synthesis of m-sulfamoylbenzamide analogues
Verlee, A., Heugebaert, T. S. A., van der Meer, T., Kerchev, P., Breusegem, F. V., & Stevens, C. V. (2017) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.13.33 · Cited by 7
Walhart, T. A., Wechsler, E. I., Ang, K.-H., Arkin, M. R., Tugizov, S. M., & Palefsky, J. M. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219860771 · Cited by 7
“Repurposing drugs with known human safety profiles could accelerate the transition of drug and disease mechanisms coupled with clinical translation to human applications and decreased cost and time of bringing a new drug to market.(10) Therefore, our overarching conceptualization and goal was to develop an HTS assay t…”
BackgroundMethodInfluentialDevelopment of novel highly sensitive methods to detect endogenous cGAMP in cells and tissue
Miyakawa, S., Okui, T., Shiraishi, T., Yoshihara, T., Hirayama, M., Satomi, Y., Hamada, T., Nishida, M., Akimoto, C., & Sato, S. (2020) · Journal of Immunological Methods · doi:10.1016/j.jim.2020.112751 · Cited by 8
Greenidge, P. A., Blommers, M. J. J., Priestle, J. P., & Hunziker, J. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00892 · Cited by 7
Bührmann, M., Kallepu, S., Warmuth, J. D., Wiese, J. N., Ehrt, C., Vatheuer, H., Hiller, W., Seitz, C., Levy, L. M., Czodrowski, P., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00187 · Cited by 7
Bell, A., Bradley, J., Everett, J. R., Knight, M., Loesel, J., Mathias, J. P., McLoughlin, D. J., Mills, J. E. J., Sharp, R. E., Williams, C., et al. (2013) · Molecular Diversity · doi:10.1007/s11030-013-9438-x · Cited by 7
“High throughput screening (HTS) [5,6] is a major part of the lead discovery operations in most large pharmaceutical companies [7] and it is capital and resource intensive.”
BackgroundA high throughput array microscope for the mechanical characterization of biomaterials
Cribb, J., Osborne, L. D., Hsiao, J. P.-L., Vicci, L., Meshram, A., O’Brien, E. T., Spero, R. C., Taylor, R. M., & Superfine, R. (2015) · Review of Scientific Instruments · doi:10.1063/1.4907705 · Cited by 7
Bialkowska, A. B., & Yang, V. W. (2012) · Future Oncology · doi:10.2217/fon.12.19 · Cited by 7
“Extensive reviews regarding the characteristics, methodology and evaluation of HTS have previously been published [1,2].”
BackgroundBioinformatics Approaches for Genomics and Post Genomics Applications of Anticancer Plants
Mehta, A., & Hasija, Y. (2018) · Springer eBooks · doi:10.1007/978-981-10-8417-1_12 · Cited by 7
Using Machine Learning To Inform Decisions in Drug Discovery: An Industry Perspective
Green, D. V. S. (2019) · ACS symposium series · doi:10.1021/bk-2019-1326.ch005 · Cited by 8
Self-citationPiptides: New, Easily Accessible Chemotypes For Interactions With Biomolecules
Arancillo, M., Taechalertpaisarn, J., Liang, X., & Burgess, K. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202015203 · Cited by 7
Edrada‐Ebel, R., Aevarsson, A., Polymenakou, P., Hentschel, U., Carettoni, D., Day, J., Green, D. H., Hreggviðsson, G. Ó., Harvey, L., & McNeil, B. W. J. (2018) · Grand challenges in biology and biotechnology · doi:10.1007/978-3-319-69075-9_12 · Cited by 10
Self-citationZhao, X., Wang, J., Liu, G. X., Fan, T., Zhang, Y. J., Yu, J., Wang, S. X., Li, Z. J., Zhang, Y. Y., & Zheng, X. H. (2015) · RSC Advances · doi:10.1039/c5ra10812h · Cited by 8
Dwikarina, A., Bayati, M., Efrat, N., Roy, A., Lei, Z., Ho, K., Sumner, L. W., Greenlief, C. M., Thomas, A. L., Applequist, W. L., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.13.611920 · Cited by 7
“Both are necessary for discovering and characterizing newly identified compounds in the drug discovery process 23,24 .”
BackgroundExperimental Test and Evaluation of Autonomous Underwater Vehicles
Keane, J., & Joiner, K. (2020) · Australian Journal of Multi-Disciplinary Engineering · doi:10.1080/14488388.2020.1788228 · Cited by 6
“…this by reducing the total number of test cases while achieving a predetermined coverage level and is in accepted use in pharmaceutical (Baker 2010; Macarron et al., 2011), genetics (Leek et al. 2010), material science (Muster et al. 2011) and software development (Hagar et al. 2015;…”
BackgroundAgboola, O. E., Agboola, S. S., Shaleye, A. B., Adedeji, O. S., Aribigbola, T. C., & Oyinloye, B. E. (2026) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2026.109461 · Cited by 9
Mitra, K., Samanta, S., & Ghorai, U. K. (2026) · Chemical Society Reviews · doi:10.1039/d6cs00031b · Cited by 6
Hat die Chemie eine Zukunft bei therapeutischen Innovationen?
Meunier, B. (2012) · Angewandte Chemie · doi:10.1002/ange.201202506 · Cited by 6
Pharmacological Screening: Drug Discovery
Nemmani, K. V. S. (2021) · Springer eBooks · doi:10.1007/978-981-15-5534-3_7 · Cited by 6
On drug discovery against infectious diseases and academic medicinal chemistry contributions
Janin, Y. L. (2022) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.18.141 · Cited by 7
Synergizing Anti-Cancer Drug Combinations With Dual-View Hypergraph Representation Fusion
Yu, J., Chen, N., Cao, L., Gao, M. Y., Liu, D., Wang, F., Lin, Q., Li, X., & Wong, K. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3511657 · Cited by 7
“However, this technology requires expensive infrastructure and skilled operators to handle the complicated experiments [6].”
Qualitative pharmacology in a quantitative world: diminishing value in the drug discovery process
Williams, M. J. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.04.002 · Cited by 6
A Design of Experiment Approach to Optimize an Image Analysis Protocol for Drug Screening
Lanati, A., Poli, C., Imberti, M., Menegon, A., & Grohovaz, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-23497-7_5 · Cited by 6
Azarias, C., Ponce‐Vargas, M., Navizet, I., Fleurat‐Lessard, P., Romieu, A., Guennic, B. L., Richard, J., & Jacquemin, D. (2018) · Physical Chemistry Chemical Physics · doi:10.1039/c8cp01587b · Cited by 6
Wang, Y., Xiao, L., Chen, Y.-K., Wu, P., Chen, Y., Hu, S. C., & Yuan, S. F. (2020) · ACS Omega · doi:10.1021/acsomega.0c00640 · Cited by 6
Synthetic inhibitor leads of human tropomyosin receptor kinase A ( h TrkA)
Subramanian, G., Vairagoundar, R., Bowen, S. J., Roush, N. S., Zachary, T., Javens, C., Williams, T., Janssen, A., & Gonzales, A. J. (2020) · RSC Medicinal Chemistry · doi:10.1039/c9md00554d · Cited by 6
Kim, S., Kang, S., Choe, J., Moon, C., Choi, H., Kim, J., & Choi, J.-W. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c04923 · Cited by 7
Zhang, J., Liu, C., Qiao, Y., Wei, M., Guan, W., Mao, Z., Qin, H., Fang, Z. D., & Guo, K. (2023) · Chemical Science · doi:10.1039/d2sc05768a · Cited by 6
Machine Learning in Drug Design
Engkvist, O., Mervin, L., Chen, H., & Ran, T. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00231 · Cited by 7
Engineering biology and automation–Replicability as a design principle
Bultelle, M., Casas, A., & Kitney, R. I. (2024) · Engineering Biology · doi:10.1049/enb2.12035 · Cited by 6
“High ‐ throughput screening once again offers an example [108], as it has been accused of being a contributory factor to the decline in reduced productivity in the pharmaceutical industry (poor ‐ quality data and insufficient hit rate).”
BPP: a platform for automatic biochemical pathway prediction
Yi, X., Liu, S., Wu, Y., McCloskey, D., & Meng, Z. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae355 · Cited by 6
“To identify potential links or attributes within biochemical pathway networks, existing methods mainly rely on trial-and-error experimental procedures [1, 27–30].”
MethodDualSyn: A dual-level feature interaction method to predict synergistic drug combinations
Chen, Z., Li, Z., Shen, X., Liu, Y., Lin, X., Zeng, D., & Zeng, X. (2024) · Expert Systems with Applications · doi:10.1016/j.eswa.2024.125065 · Cited by 6
De novo design of mIDH1 inhibitors by integrating deep learning and molecular modeling
Sun, D., Xu, L., Tong, M., Zhao, W., Zhang, W., Liang, J., Liu, X., & Wang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1491699 · Cited by 8
“Studies have shown that the number of chemically synthesizable active compounds is estimated to be 10 30 to 10 60 , which is a huge amount of work and inef fi cient for traditional drug discovery based high throughput screening (Polishchuk et al., 2013; Macarron et al., 2011).”
BackgroundJati, A., Das, S. K., Shukla, A. N., & Maji, B. (2024) · ChemCatChem · doi:10.1002/cctc.202401341 · Cited by 6
FragMAX Facility for Crystallographic Fragment and Ligand Screening at MAX IV
Sandesh Kanchugal, P., Jagudin, E., Lima, G. M. A., Talibov, V., Begum, A., Nan, J., Eguiraun, M., Gonzalez, A. M., Sèle, C., Nyblom, M., et al. (2025) · Applied Research · doi:10.1002/appl.202400263 · Cited by 6
Rahardhian, M. R. R., Sumiwi, S. A., Susilawati, Y., & Muchtaridi, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073068 · Cited by 7
“− Lower Ki indicates higher affinity and greater potency as an inhibitor [35].”
Label-Free Screening Technologies
Ye, F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12330-3 · Cited by 6
Prospective Assessment of Virtual Screening Heuristics Derived Using a Novel Fusion Score
Pertusi, D. A., O’Donnell, G. T., Homsher, M. F., Solly, K. J., Patel, A., Stahler, S. L., Riley, D., Finley, M., Finger, E. N., Adam, G. C., et al. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217706058 · Cited by 6
Dark chemical matter in public screening assays and derivation of target hypotheses
Jasial, S., & Bajorath, J. (2017) · MedChemComm · doi:10.1039/c7md00426e · Cited by 6
Cilibrizzi, A., Floresta, G., Abbate, V., & Giovannoni, M. P. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1518960 · Cited by 6
New Spiro[cycloalkane-pyridazinone] Derivatives with Favorable Fsp3 Character
Für, C. S., & Bölcskei, H. (2020) · Chemistry · doi:10.3390/chemistry2040055 · Cited by 6
“High-throughput screening (HTS) [1,2] is a widely used method, which needs a large number of compounds.”
MethodInfluentialVirtual screening of phytochemicals for drug discovery
Shreya, S., Shweta, S., Dagur, P., Rakshit, G., & Ghosh, M. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90593-0.00006-x · Cited by 7
Rai, S., Shukla, S., Scotti, L., & Mani, A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230807151708 · Cited by 6
IMMUNOHISTOCHEMICAL ANALYSIS OF THE STEM CELL MARKER LGR5 IN PEDIATRIC LIVER DISEASE
Khan, Z., Orr, A. V., Michalopoulos, G. K., & Ranganathan, S. (2016) · Pediatric and Developmental Pathology · doi:10.1177/1093526616686244 · Cited by 6
“Interestingly, HPCs have been identified in pediatric liver diseases prior to the development of significant fibrosis, suggesting an early response to liver injury.(30,31) Recently, Kuo et al.”
BackgroundGoing Small: Using Biophysical Screening to Implement Fragment Based Drug Discovery
Bowling, J. J., Shadrick, W. R., Griffith, E. C., & Lee, R. E., Jr. (2016) · InTech eBooks · doi:10.5772/66423 · Cited by 6
“These target‐based programs tend to rely on screening the highest practical number of chemical entities from their screening libraries, sometimes accumulating millions of compounds [1].”
BackgroundKim, T. G., Lee, J., Lee, M. Y., Kim, K.-U., Lee, J. H., Park, C. H., Lee, B. H., & Oh, K. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00283 · Cited by 6
Mettananda, S., Clark, K., Fisher, C. A., Sloane‐Stanley, J., Gibbons, R. J., & Higgs, D. R. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.01.001 · Cited by 6
“With the current need for high throughput platforms for screening small molecules affecting erythropoiesis, validated erythroid culture systems optimised for such smallscale assays are required (9).”
BackgroundIn silico docking and drug design of herbal ligands for anticancer property
Waghulde, S., Kale, M., & Patil, V. (2018) · Journal of Pharmacognosy and Phytochemistry · doi:10.22271/phyto.2018.v7.isp6.1.19 · Cited by 6
“22 Since molecular docking plays a central role in predicting protein-ligand interactions it has been extensively used for drug hit discovery and lead Optimization [6-18].”
BackgroundLiu, Z., Singh, S. B., Zheng, Y., Lindblom, P., Tice, C. M., Dong, C., Zhuang, L., Zhao, Y., Kruk, B. A., Lala, D. S., et al. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00198 · Cited by 7
Mejía‐Manzano, L. A., Vázquez‐Villegas, P., & González‐Valdez, J. (2020) · Advances in Polymer Technology · doi:10.1155/2020/6163904 · Cited by 6
“0eir benefits include fast testing, low cost, and high-quality data [71].”
BackgroundBuild–Couple–Transform: A Paradigm for Lead-like Library Synthesis with Scaffold Diversity
Uguen, M., Davison, G., Sprenger, L. J., Hunter, J. H., Martin, M. P., Turberville, S., Watt, J. E., Golding, B. T., Noble, M. E. M., Stewart, H. L., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00897 · Cited by 6
Towards Exploring Large Molecular Space: An Efficient Chemical Genetic Algorithm
Zhu, J.-F., Hao, Z., Liu, Q., Yin, Y., Lu, C., Huang, Z., & Chen, E. (2022) · Journal of Computer Science and Technology · doi:10.1007/s11390-021-0970-3 · Cited by 6
“Traditional chemical methods, like high throughput screening (HTS) [15] and high through-put virtual screening (HTVS) [16] , narrow the feasible space.”
BackgroundDeep Scaffold Hopping with Multi-modal Transformer Neural NetworksPreprint
Zheng, S., Lei, Z., Ai, H., Chen, H., Deng, D., & Yang, Y. (2020) · ChemRxiv · doi:10.26434/chemrxiv.13011767 · Cited by 6
Modern Automation in Organic Synthesis Laboratories
Miéville, P., & de Nanteuil, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-96025-0.00047-8 · Cited by 6
Liu, C., Hoang-Phou, S. A., Ye, C., Laurence, E. J., Laurence, M. J., Fong, E. J., Hammond, N. M., Vannest, B. D., Watkins, N. N., Laurence, T. A., et al. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c05485 · Cited by 5
Oulladji, L., Saadallah, M., Guellil, Z., Abbad, H., & Bekhti, H. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108532 · Cited by 6
Romero, O., & Geddes‐McAlister, J. (2025) · mBio · doi:10.1128/mbio.02303-24 · Cited by 6
“Once validated, the targeted molecule can be used for high-throughput screening (HTS) of large compound libraries or rational drug design (135).”
Unlocking nature’s medicine cabinet through Drosophila–Driven exploration
Sheng, X. Q., He, J., & Zhang, L. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157123 · Cited by 5
Integrating Computational and Experimental Approaches in 21st Century Drug Design
Kumar, R., Khan, S. K., Yadav, A. K., & Reetu (2025) · Journal of Drug Discovery and Health Sciences · doi:10.21590/jddhs.02.02.04 · Cited by 6
Ge, J., Han, P., Xu, R., Wang, S., Li, M., & Song, T. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01310 · Cited by 5
Wu, Z., Zeng, B., Seah, D. H., Ng, I. Z. R., Ding, R. H., Zhang, T., Kalaichelvan, M., You, R., & Fong, E. L. S. (2025) · Advanced Materials · doi:10.1002/adma.202512252 · Cited by 5
He, S., Meister, D. L., Khan, S., Mohammadzadeh, A., Delgadillo-Silva, L. F., Rutter, G. A., Trant, J. F., & Lim, G. E. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08150-6 · Cited by 5
Teimouri, H., Haghighijoo, Z., Baumgartner, T. J., Singh, A. K., Wadsworth, P. A., Zhang, C., Chen, H., Zhou, J., & Laezza, F. (2025) · Journal of Cheminformatics · doi:10.1186/s13321-025-01122-0 · Cited by 6
“However, these approaches are frequently limited by a lack of mechanistic insight into the structural or electronic properties that drive strong protein binding and functional modulation [11, 12].”
Jadhav, V., Gurgude, R., & Sawant, R. (2025) · Next research. · doi:10.1016/j.nexres.2025.100986 · Cited by 6
Elkhatat, A. M., & Al‐Muhtaseb, S. A. (2026) · Applied Intelligence · doi:10.1007/s10489-026-07326-7 · Cited by 6
“Reported hit-rate enrichment is one of the clearer opera - tional metrics; if AI-designed libraries yield > 30% actives in assays—contrasted with < 1% in naïve screening—then most of the chemistry that would have been made to find those actives simply never happens [164 , 165].”
Exploring chemical diversity via a modular reaction pairing strategy
Loh, J. K., Yoon, S. Y., Samarakoon, T. B., Rolfe, A., Porubsky, P. R., Neuenswander, B., Lushington, G. H., & Hanson, P. R. (2012) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.8.147 · Cited by 5
HTSvis: a web app for exploratory data analysis and visualization of arrayed high-throughput screens
Scheeder, C., Heigwer, F., & Boutros, M. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx319 · Cited by 7
Bhuyan, S., Das, D., Chakraborty, A., Mandal, S., Dhanabal, K., & Roy, B. (2021) · Chemistry - An Asian Journal · doi:10.1002/asia.202101123 · Cited by 5
Automated and intelligent chemical synthesis
Yu, L., Lin, C., Zhou, D., Cao, L., & Wang, C. (2022) · Scientia Sinica Chimica · doi:10.1360/ssc-2022-0192 · Cited by 5
Stepping towards pollen DNA metabarcoding: A breakthrough in forensic sciences
Wasti, Q. Z., Sabar, M. F., Farooq, A., & Khan, M. U. (2023) · Forensic Science Medicine and Pathology · doi:10.1007/s12024-023-00770-8 · Cited by 5
“These techniques form the basis of genomic and molecular biology studies [44].”
Mitigating Pathogenesis for Target Discovery and Disease Subtyping
Strobl, E. V., Lasko, T. A., & Gamazon, E. R. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108122 · Cited by 5
ParaCPI: A Parallel Graph Convolutional Network for Compound-Protein Interaction Prediction
Zhang, L., Zeng, W., Chen, J., Chen, J., & Li, K. (2024) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2024.3404889 · Cited by 5
“Although high-throughputscreening[1]remainsareliablemethodforde-tecting interactions between compounds and proteins, building large compound screening libraries in practical applications is difficult [2].”
Facets of click-mediated triazoles in decorating amino acids and peptides
Bag, S. S., Banerjee, A., Sinha, S., & Jana, S. (2024) · Chemical Communications · doi:10.1039/d4cc03887h · Cited by 5
Ruthenium-Based Small-Molecule Complexes: A Promising Approach for Drug Discovery
Purohit, P., Bhatt, A., & Mittal, R. K. (2025) · Synlett · doi:10.1055/s-0043-1773514 · Cited by 5
High-Throughput Screening Data Analysis
Gubler, H. (2016) · Statistics for biology and health · doi:10.1007/978-3-319-23558-5_5 · Cited by 6
Rapid Compound Integrity Assessment for High-Throughput Screening Hit Triaging
Shou, W. Z., Gerritz, S. W., Harden, D., Lawrence, R. M., Chase, P. S., Chin, J. A., Surti, N., Lippy, J., Weller, H. N., Nielsen, J. M., et al. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220919097 · Cited by 5
Metadata
- Authors
- Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., Schopfer, U., & Sittampalam, G. S.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Novartis (United States) (US)
- Abbott (United States) (US)
- Sanofi (France) (FR)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- University of North Carolina at Chapel Hill (US)
- The University of Kansas Cancer Center (US)
- Novartis (Switzerland) (CH)
- Pfizer (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-03
- Volume
- 10
- Issue
- 3
- Pages
- 188-195
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2031441006
- Cited by
- 1,364
- References
- 65
- Citations by year
- 2026: 113 · 2025: 117 · 2024: 99 · 2023: 103 · 2022: 82 · 2021: 107 · 2020: 106 · 2019: 77 · 2018: 105 · 2017: 87 · 2016: 96 · 2015: 64 · 2014: 61 · 2013: 73 · 2012: 54
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- high-throughput screening, drug discovery, chemical biology
- MeSH terms
- Animals, Drug Evaluation, Preclinical, Humans, Drug Design, Biomedical Research, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.